MiMedx provided update on LCDs regarding skin substitute

MiMedx (MDXG) provided the following update on the Local Coverage Determinations, LCDs, regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.” These new LCDs were originally proposed in April 2024, with a comment period that concluded in June 2024. The LCDs are now set to become effective on February 12, 2025. As a result of industry feedback, the final LCDs have been modified in the following key areas: The number of separate treatment applications a patient can receive was raised from 4 to 8; Treatment duration increased from 12 to 16 weeks; Importantly, the MACs have maintained their insistence on well-powered, peer-reviewed clinical evidence as a prerequisite for reimbursement.